Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2

Publisher： Karger

E-ISSN： 1423-0267|229|4|195-202

ISSN： 0030-3755

Source： Ophthalmologica, Vol.229, Iss.4, 2013-04, pp. : 195-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Pilot Study on the Combination Treatment of Reduced-Fluence Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 225, Iss. 4, 2011-02 ,pp. : 200-206

Karger

Access to resources Recommend Favorite

How Prevalent is Macular Telangiectasia Type 2?

By Chew Emily Y.  

Ophthalmic Epidemiology, Vol. 19, Iss. 4, 2012-08 ,pp. : 183-184

Informa Healthcare

Access to resources Recommend Favorite

Unusual Presentations of Type 2 Idiopathic Macular Telangiectasia

By  

Ophthalmologica, Vol. 230, Iss. 3, 2013-08 ,pp. : 126-130

Karger

Access to resources Recommend Favorite

Intravitreal Bevacizumab for Type 2 Idiopathic Macular Telangiectasia

By  

Ophthalmic Research, Vol. 49, Iss. 4, 2013-01 ,pp. : 205-208

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 45, Iss. 3, 2010-09 ,pp. : 129-134

Karger

Access to resources Recommend Favorite